| First Author | Guo P | Year | 2024 |
| Journal | Elife | Volume | 13 |
| PubMed ID | 38346162 | Mgi Jnum | J:346895 |
| Mgi Id | MGI:7619152 | Doi | 10.7554/eLife.86168 |
| Citation | Guo P, et al. (2024) A methylation-phosphorylation switch controls EZH2 stability and hematopoiesis. Elife 13 |
| abstractText | The Polycomb Repressive Complex 2 (PRC2) methylates H3K27 to regulate development and cell fate by transcriptional silencing. Alteration of PRC2 is associated with various cancers. Here, we show that mouse Kdm1a deletion causes a dramatic reduction of PRC2 proteins, whereas mouse null mutation of L3mbtl3 or Dcaf5 results in PRC2 accumulation and increased H3K27 trimethylation. The catalytic subunit of PRC2, EZH2, is methylated at lysine 20 (K20), promoting EZH2 proteolysis by L3MBTL3 and the CLR4(DCAF5) ubiquitin ligase. KDM1A (LSD1) demethylates the methylated K20 to stabilize EZH2. K20 methylation is inhibited by AKT-mediated phosphorylation of serine 21 in EZH2. Mouse Ezh2(K20R/K20R) mutants develop hepatosplenomegaly associated with high GFI1B expression, and Ezh2(K20R/K20R) mutant bone marrows expand hematopoietic stem cells and downstream hematopoietic populations. Our studies reveal that EZH2 is regulated by methylation-dependent proteolysis, which is negatively controlled by AKT-mediated S21 phosphorylation to establish a methylation-phosphorylation switch to regulate the PRC2 activity and hematopoiesis. |
